Application of two lines of chemotherapy: gemcitabine with nab-paclitaxel and liposomal irinotecan with 5-fluorouracil and leucovorin in patient with advanced pancreatic adenocarcinoma

• Authors: Krystyna Ostrowska-Cichocka , Marek Z. Wojtukiewicz
• Languages of publication: EN

Abstracts

EN

Pancreatic cancer is a disease with high mortality. It is predicted to become the second leading cause of cancer death in some regions of the world. Frequent diagnosis at an advanced stage contributes to 5-year survival at a highly unsatisfactory level of 2–9%. Due to the lack of early symptoms, nearly 80% of patients receive a diagnosis when distant metastases develop. So far, the most frequently used programs in the treatment of patients with pancreatic cancer in the stage of neoplastic spreading include: FOLFIRINOX (oxaliplatin, 5-fluorouracil, irinotecan, leucovorin), gemcitabine alone or in combination with nab-paclitaxel or erlotinib. Based on the results of the phase III study NAPOLI-1, liposomal irinotecan in combination with 5-fluorouracil (5-FU) and leucovorin (LV ) was approved as the first regimen for use in the second or subsequent line of therapy in patients with advanced pancreatic cancer previously treated with gemcitabine. This paper presents a case of a patient with advanced pancreatic cancer who was treated with two lines of chemotherapy – gemcitabine in combination with nab-paclitaxel and liposomal irinotecan with 5-FU/LV . The treatment was well tolerated and was considered a valuable therapeutic option. A 2-year overall survival was obtained from the diagnosis of the disease.

Keywords

EN

advanced pancreatic cancer; gemcitabine in combination with nab-paclitaxel; liposomal irinotecan with 5-FU/LV

Discipline

• MEDICINE: MEDICINE

• Publisher: Medical Education
• Journal: OncoReview
• Year: 2021
• Volume: 11
• Issue: 3
• Pages: 68-72

Contributors

author

Krystyna Ostrowska-Cichocka

• Department of Clinical Oncology with the Subdivision of Daily Chemotherapy, Dr. Ewa Pilecka Memorial Bialystok Cancer Center

author

Marek Z. Wojtukiewicz

• 1. Department of Clinical Oncology with the Subdivision of Daily Chemotherapy, Dr. Ewa Pilecka Memorial Bialystok Cancer Center. 2. Department of Oncology, Medical University of Bialystok

References

• 1. Ducreux M, Cuhna A. Sa, Caramella C et al. Cancer of the pancreas: ESMO Clinical Practice.Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015; 26(suppl 5): v56-v68.
• 2. Lambert A, Schwarz L, Borbath I et al. An update on treatment options for pancreatic adenocarcinoma. Adv Med Oncol. 2019; 11: 1143.
• 3. McGuigan A, Kelly P, Turkington RC et al. Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes. World J Gastroenterol. 2018; 24(43): 4846-61.
• 4. Taieb J, Abdallah R. How I treat pancreatic cancer. ESMO Open. 2020; 4: e000818. https://doi.org/10.1136/.Esmo open-2020-0008.
• 5. Moore MJ, Goldstein D, Hamm J et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007; 25: 1960-6.
• 6. Jassem J, Krzakowski M, Potemski P. Nowotwory układu pokarmowego. 2nd ed. Via Medica, Gdańsk 2019.
• 7. Conroy T, Desseigne F, Ychou M et al. FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer. N Engl J Med. 2011; 364: 1817-25.
• 8. Tempero MA, Malafa MP, Chiorean EG et al. Pancreatic adenocarcinoma, version 1.2021. NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019; 17(3): 202-10.
• 9. Tehfe M, Dowden S, Kennecke H et al. nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma: Canadian Subgroup Analysis of the Phase 3 MPACT Trial. Adv Ther. 2016; 33(5): 747-59.
• 10. Von Hoff DD, Ervin T, Arena FP et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013; 369: 1691-703.
• 11. Czyżykowski R, Janiak M, Krakowska M et al. Palliative systemic treatment of patients with pancreatic cancer – should reimbursement of nab-paclitaxel change the current management paradigm? Oncol Clin Pract. 2017; 13: 8-13.
• 12. Wang-Gillam A, Li C-P, Bodoky G et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet. 2016; 387: 545-57.
• 13. Klank-Sokołowska E, Kucharewicz M, Wojtukiewicz MZ. Nanoliposomalny irynotekan – nowe perspektywy leczenia uogólnionego raka trzustki. Onkol Prakt Klin. 2019; 5: 1-9.

• Document Type: article